CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six months ended June 30, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated.
“The second quarter 2021 was an important period for Trillium, during which time we communicated our go-forward strategy and began executing against it,” said Jan Skvarka, Trillium’s President and CEO. “We announced seven priority indications and nine patient settings, with six studies expected to initiate in 2021. As of today, we have already initiated four studies, including in multiple myeloma, acute myeloid leukemia (p53 mutated and wild type), and leiomyosarcoma. With our operating plan being on track, our focus is on strong execution, to ensure a robust flow of new data starting in 4Q 2021 and 2022. We continue to be very excited about Trillium’s position as a leading CD47 company.”
Second Quarter 2021 Financial Results
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
For more information visit: www.trilliumtherapeutics.com
Caution Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable United States federal securities laws and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The use of words such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. Forward-looking statements in this press release include express or implied statements regarding the therapeutic potential and monotherapy activity of our programs, our clinical development plans, including the expected timing of the release of further data on Trillium’s TTI-622 and TTI-621 studies and our expectations with respect to the timing of clinical development milestones, including with respect to enrolling patients in Phase 1b/2 studies in hematological and solid tumor malignancies, and our expected cash runway. With respect to the forward-looking statements contained in this press release, Trillium has made numerous assumptions regarding, among other things: the impact of the COVID-19 pandemic on its operations, the effectiveness and timeliness of preclinical and clinical trials; and the completeness, accuracy and usefulness of the data. While Trillium considers these assumptions to be reasonable, these assumptions are inherently subject to significant scientific, business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause Trillium’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. A discussion of risks and uncertainties facing Trillium appears in Trillium’s Annual Report on Form 10-K for the year ended December 31, 2020, with the U.S. Securities Exchange Commission, each as updated by Trillium’s continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Trillium disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Trillium Therapeutics Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(amounts in thousands, except share and per share data)
Three months ended June 30, 2021 |
Three months ended June 30, 2020 |
Six months ended June 30, 2021 |
Six months ended June 30, 2020 |
||||||||||||
Revenue | $ | 10 | $ | 115 | $ | 10 | $ | 115 | |||||||
Operating expenses | |||||||||||||||
Research and development expenses | 13,999 | 7,174 | 19,923 | 12,162 | |||||||||||
General and administrative expenses | 4,677 | 16,697 | 10,067 | 28,372 | |||||||||||
Total operating expenses | 18,676 | 23,871 | 29,990 | 40,534 | |||||||||||
Operating loss | (18,666 | ) | (23,756 | ) | (29,980 | ) | (40,419 | ) | |||||||
Other income (expense) | |||||||||||||||
Interest income, net | 352 | 441 | 881 | 853 | |||||||||||
Net foreign currency gain (loss) | 13 | 125 | (22 | ) | 101 | ||||||||||
Total other income, net | 365 | 566 | 859 | 954 | |||||||||||
Net loss before income taxes | (18,301 | ) | (23,190 | ) | (29,121 | ) | (39,465 | ) | |||||||
Income tax expense | 98 | 28 | 140 | 51 | |||||||||||
Net loss | (18,399 | ) | (23,218 | ) | (29,261 | ) | (39,516 | ) | |||||||
Net loss per share, basic and diluted | (0.18 | ) | (0.28 | ) | (0.28 | ) | (0.53 | ) | |||||||
Weighted average number of common | |||||||||||||||
shares used in computing net loss per | |||||||||||||||
share, basic and diluted | 103,782,222 | 83,752,156 | 103,395,342 | 74,637,214 |
Trillium Therapeutics Inc.
Selected Condensed Consolidated Balance Sheet Data
(unaudited)
(amounts in thousands)
June 30, 2021 | December 31, 2020 | ||||
Cash and cash equivalents, and marketable securities | $ | 264,537 | $ | 291,165 | |
Total assets | 273,684 | 300,822 | |||
Total liabilities | 14,118 | 21,975 | |||
Total stockholders’ equity | 259,566 | 278,847 |
Company Contact:
Rosemary Harrison
SVP, Corporate Development and Strategy
Trillium Therapeutics Inc.
857-412-7029 x225
investors@trilliumtherapeutics.com
www.trilliumtherapeutics.com
Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com
SenderraCare+ is a game-changer for providers and patients alike. It simplifies the time-consuming process and…
NEW YORK, July 16, 2024 /PRNewswire/ -- The global industrial laser market size is estimated…
How one employee's upbringing and career journey have motivated her to fight inequities around the…
WASHINGTON, DC / ACCESSWIRE / July 16, 2024 / The Alliance for Safe Biologic Medicines…
Comprehensive Back-to-School Event on Saturday, July 20, 2024, Will Feature Life-Saving Cardiac Screenings Alongside Free…
CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Application for Innovative…